EMEA-003552-PIP01-23 - paediatric investigation plan

human rabies immunoglobulin

Key facts

• Active Substance:
  human rabies immunoglobulin
• Therapeutic area:
  Infections and infestations
• Decision number:
  P/0175/2024
• PIP number:
  EMEA-003552-PIP01-23
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Prevention of rabies viral infection
• Route(s) of administration:
  Intramuscular use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  03/06/2024

Decision

P/0175/2024: EMA decision of 3 May 2024 on the agreement of a paediatric investigation plan for Human rabies immune globulin (EMEA-003552- PIP01-23)

Reference Number: EMA/182144/2024